![]() This report has listed the top laboratory animals and supplies suppliers, SLA agreement insights, and the selection and negotiation strategies that buyers must undertake to achieve optimal procurement in this market. ![]() The Top Suppliers in the Laboratory Animals and Supplies Enlisted in this Report: Subscribe to our procurement platform to get instant access to over 1000 market-ready procurement intelligence reports without any additional costs or commitment. These factors are contributing to the growing demand for animal models and supplies. Moreover, the growth of the CRO industries in India, China, Taiwan, and Korea is resulting in a greater number of pre-clinical studies being conducted there. APAC’s large market share is attributed to the rising investments by biopharmaceutical companies in R&D activities, especially in countries such as India, China, and Singapore. In terms of regional spend, APAC owns the majority share of the market, accounting for approximately 40% of the total spend on laboratory animals and supplies. This is propelling the use of lab animals among pharmaceutical companies, thereby contributing to the growth of laboratory animals and supplies market spend. Advancements in genetic mapping and genetic modeling are enabling suppliers to provide better animal breeds and genetic combinations. The necessity of newer medicines and the simultaneous emergence of the same is increasing the need for lab animals from the pharmaceutical industry to conduct testing of the medicines. Read the 83-page research report with TOC and LOE on "The Global Laboratory Animals and Supplies Market – Procurement Intelligence Report, Pricing Outlook in Geographies that include APAC, North America, South America, and MEA, top suppliers, supplier selection and negotiation strategies, and insights into best practices to optimize procurement spend.” LONDON-( BUSINESS WIRE)-SpendEdge has been monitoring the global laboratory animals and supplies market and the market is poised to experience spend growth of over USD 300 million between 2017-2022 at a CAGR of over 6% during the forecast period.
0 Comments
Leave a Reply. |